|
|
||||||||
1 From the Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong; and 2 The Wilmer Ophthalmological Institute, Johns Hopkins University and Hospital, Baltimore, Maryland.
| Abstract |
|---|
|
|
|---|
METHODS. A carotenoid-containing fraction (P1) from an extract of F. lycii (equivalent to 2.2 mg zeaxanthin) was fed to three rhesus monkeys for 6 weeks as a daily dietary supplement through a nasogastric tube. Three other monkeys were fed with the vehicle (olive oil) similarly for 4 weeks as a control. Another three animals were fed with normal diet only. All animals were killed 4 hours after the last dose. Samples of serum, liver, spleen, brain, and retina were analyzed for zeaxanthin and lutein by high-pressure liquid chromatography.
RESULTS. The basal levels of zeaxanthin and lutein in the monkey sera were 3.0 ± 1.6 ng/ml (range, 2.34.8) and 31.5 ± 12.2 ng/ml (range, 22.342.5), respectively. Serum levels of zeaxanthin and lutein in the P1-fed group were significantly higher than those of vehicle control (P < 0.05). Besides the retina, the liver had the highest zeaxanthin and lutein levels, whereas the levels in the brain were undetectable. P1 supplement appeared to elevate zeaxanthin levels in liver and spleen. The level of lutein was higher than that of zeaxanthin in the maculae of rhesus monkeys. However, there were no detectable carotenoids in the peripheral and the equatorial regions of the monkey retina. P1 treatment elevated zeaxanthin density but not lutein in the macula.
CONCLUSIONS. Serum levels and macular density of zeaxanthin was raised by feeding a carotenoid-containing fraction of F. lycii. Therefore, F. lycii is a good dietary source of zeaxanthin supplement.
| Introduction |
|---|
|
|
|---|
Fructus lycii or gou qi zi, the dried fruit of Lycium barbarum, is a red berry prescribed by Chinese herbalists as a health tonic and a therapeutic agent for a number of eye diseases ranging from cataract to retinitis pigmentosa and glaucoma.13 Chromatographic study of F. lycii indicates a high content of zeaxanthin (300 µg/g) but a negligible amount of lutein (<3 µg/g) in the berries.14 15 Khachik et al.16 found elevated serum zeaxanthin levels in three human subjects after taking a zeaxanthin extract from the dried berries of Lycium chinense, a species closely related to L. barbarum. However, the effect on the level of macular pigment in these subjects was not determined.
Although plasma or serum levels of carotenoids in several primates such as Saimiri sciureus, Macaca fascicularis,17 and others18 as well as the relative distribution of macular carotenoids in M. fascicularis19 and humans20 had been studied, the relative distribution of zeaxanthin and lutein in the serum and the macula of rhesus monkeys (Macaca mulatta) has not been determined. There are few reports on the relative distribution of zeaxanthin and lutein in liver or other organ such as spleen in primates.21 22
In this study we fed a chromatographic fraction from an extract of F. lycii to three rhesus monkeys for 6 weeks to study the levels of zeaxanthin and lutein in serum, retina, liver, spleen, and brain by high-pressure liquid chromatography (HPLC).
| Materials and Methods |
|---|
|
|
|---|
Administration of P1 and Vehicle to the Monkeys
Nine female rhesus monkeys (M. mulatta) were used in
this study. They were kept in the Guangdong Shunde Institute of
Laboratory Animals, China. All animals were examined and found to be
healthy. The study was approved by the Animal Research Ethics Committee
of the Chinese University of Hong Kong and followed the guidelines of
the ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research.
The monkeys were fed a normal diet of monkey chow and supplementary fruits before and throughout the experimental period. It was estimated that each monkey consumed approximately 200 g vegetable, 100 g corn, and 100 g monkey chow daily, which provided approximately 2.1 mg of total zeaxanthin and lutein. The age of the animals ranged from 12 to 18 years (15.4 ± 2.2 years; mean ± SD). Monkeys 1, 2, and 3 (mean weight: 4.4 kg; range: 4.34.6) were each given a 2-ml mixture of olive oil and ethanol (olive oil:ethanol, 1:1) through a nasogastric tube daily for 4 weeks as vehicle control supplementation. Monkeys 4, 5, and 6 (mean weight: 4.3 kg; range: 3.9- 4.5 kg) were each given P1 in 2 ml olive oil with 50% ethanol (equivalent to 7.3 g F. lycii or 2.2 mg zeaxanthin/day or 0.5 mg zeaxanthin/kg body weight/day) daily through a nasogastric tube for 6 weeks. Another three normal control animals (monkeys 7, 8, and 9; mean weight: 6.3 kg; range: 4.46.7 kg) were reared on normal monkey diet for 4 weeks and killed.
Blood and Tissue Collection
Blood (2-ml aliquots) was taken from the femoral vein of monkeys
1 to 6 four times per month before feeding with vehicle or P1
supplement. After the initiation of the feeding program, blood was
taken from each monkey twice each week. All serum samples were stored
at -80°C before processing.
At the end of the feeding period, the monkeys were anesthetized by intramuscular injection of ketamine (10 mg/kg) and killed with a pentobarbital sodium overdose followed by immediate exsanguination. A tissue sample of liver was excised from the inferior part of the right lobe. Samples of spleen and brain were excised from the superior ending closed to the cardiac orifice of the stomach and the visual cortex area 17, respectively.
All eyes were enucleated within 1 to 2 hours after exsanguination. Retina samples were taken from the macular, equatorial, and peripheral regions of all the right eyes with trephines of 3- or 6-mm internal diameter. The macular region was excised with the foveola as the center of the trephine after vitrectomy. The equator and peripheral samples were taken from the nasal and the temporal regions, respectively. There was no attempt to separate the retinal pigment epithelium during the dissection. A 3-mm trephine was used in monkeys 4, 5, and 6 accidentally, and the 6-mm trephine was used in all other monkeys. These samples were kept at -80°C until analysis. The whole eyeballs of the left eyes were fixed for histologic examination for a separate study.
Hexane Extraction of Serum and Tissue Samples
A previously described extraction method was
followed.24
Briefly, an aliquot of 0.2 ml serum sample was
mixed with an equal volume of absolute ethanol and subjected to sonic
disruption in a Sonifier (Branson Ultrasonics, Danbury, CT) for 30
seconds. The mixture was extracted with 4 volumes of hexane, followed
by vigorous mixing for 3 minutes and centrifugation at 2000g
for 10 minutes. The organic phase was collected, and the aqueous phase
was re-extracted in the same manner twice. The combined organic
fraction was evaporated to dryness under nitrogen.
Approximately 0.5-g tissue samples of liver, spleen, or brain were weighed and minced with razor blades. An aliquot of 2 ml water was added, and the tissue samples were homogenized with a rotating blender for 5 minutes. An equal volume of ethanol was added and mixed with the homogenate. The mixture was extracted with 4 volumes of hexane three times, as described. The organic extracts were combined and evaporated to dryness under nitrogen.
Samples of macular tissue were thawed and homogenized in 0.2 ml water by sonication for 1 minute. An equal amount of absolute ethanol was added, and the mixture was extracted with 4 volumes of hexane three times, as described. The combined organic extract was evaporated to dryness.
HPLC Analysis
A previously described HPLC method was used to measure serum and
tissue contents of zeaxanthin and lutein.24
Briefly, all
samples were dissolved in appropriate volumes of the mobile phase (16%
dioxane in hexane) for injection into a silica column (3.9 x 300
mm; Waters). Analysis was performed with isocratic elution at 2 ml/min.
An aliquot of 50 µl specimen was injected. Absorbance at 450 nm was
monitored by a photograph-diode array detector (Waters). Zeaxanthin and
lutein levels were determined by external standard calibration.
Recovery was determined by adding known amounts of zeaxanthin and
lutein standards to serum or tissue samples from normal monkeys and
found to be 70% to 80% depending on each batch of analysis. The
possibility that zeaxanthin metabolite coeluted with the lutein peak
was not ruled out.
| Results |
|---|
|
|
|---|
|
|
|
| Discussion |
|---|
|
|
|---|
Basal serum zeaxanthin and lutein levels in our rhesus monkeys were 10 and 3 times lower than those reported in M. fascicularis and S. sciureus, respectively.17 It was unlikely that the low serum zeaxanthin and lutein levels in our rhesus monkeys were due to a difference in dietary carotenoid contents because analysis of monkey diet (including monkey chows and fruit supplement) showed a daily intake of 2.1 mg of total zeaxanthin and lutein in our vivarium, which was comparable to the monkey diet in the study by Snodderly et al.26 Slifka et al. reported the combined zeaxanthin and lutein levels in the sera of different primates varied from nondetectable level in the golden lion tamarin to an average of 1017 ng/ml in the sooty mangabey with most of the animals having a level between 28 and 170 ng/ml.18 The combined levels of zeaxanthin and lutein in our animals ranged from 26 to 47 ng/ml (mean, 35) and remained in the lower end of the spectrum reported by Slifka et al. Therefore, different primates may have varying ability to absorb and metabolize various carotenoids, resulting in differences in serum levels of these carotenoids.
Contrary to the study by Snodderly et al.26 showing no change in the concentration of serum lutein after supplementation of zeaxanthin to squirrel monkeys, we noted a significant increase in lutein levels in the serum after P1 supplementation. Because F. lycii has a very low content of lutein (less than 1%), it is an unlikely source of serum lutein. It is possible that zeaxanthin can be converted to lutein, but there is no evidence in the literature to suggest that zeaxanthin is converted into lutein in serum or retina, whereas the reverse has been proposed by Bone et al.29 and Khachik et al.30 However, lutein and other carotenoids are present in the monkey chows and daily fruits given to the animals. It is possible that zeaxanthin or other components in the P1 extract may enhance the absorption of lutein. It is also possible that there is a metabolite of zeaxanthin coeluting with lutein that cannot be separated by the present methodology.
Lutein, cryptoxanthin, and ß-carotene are the most common carotenoids found in fruits or vegetables, while zeaxanthin is present only in minute quantities in most fruits and vegetables.30 31 32 Therefore, dietary zeaxanthin intake is very low. In addition, feeding corn and spinach, which are relatively rich in zeaxanthin, does not alter serum zeaxanthin levels.11 Recently, egg yolk was suggested to be a good dietary source of zeaxanthin.32 Plasma lutein and zeaxanthin levels were elevated by 39% and 128%, respectively, after a dietary supplement of 1.3 egg yolks daily for 4.5 weeks.33 However, the constant consumption of egg yolk would increase the risk of cardiovascular diseases by increasing low-density lipoprotein cholesterol. In our study, serum zeaxanthin concentration increased by a factor of 2.5 with feeding of an extract from 7.3 g F. lycii (equivalent to 0.55 mg zeaxanthin per kilogram body weight per day) for 6 weeks in two monkeys. The dosage is relatively low compared with the study by Snodderly et al.26 in which 2.2 mg zeaxanthin was fed each day to squirrel monkeys with body weights from 0.7 to 1.1 kg.26 Therefore, F. lycii is a good dietary source of zeaxanthin.
In a previous study, zeaxanthin was extracted from the dried fruits of L. chinense (closely related to L. barbarum) and orally taken by three human subjects as dietary supplements. A rapid elevation of serum zeaxanthin was noted.16 In spite of the low basal levels of zeaxanthin and lutein in our rhesus monkeys, we also noted a rapid increase in zeaxanthin levels in the sera of two monkeys, but not in monkey 4 which also had a low level of zeaxanthin in liver and spleen. We deemed monkey 4 a nonresponder that showed poor absorption of zeaxanthin. Nonresponders such as monkey 4 have previously been reported.11 34 We speculate that the absence of sufficient carotenoid-carrying proteins may explain the low levels of serum carotenoids irrespective of dietary intake. However, the rapid increase in serum zeaxanthin levels in the responders, even in those with low basal zeaxanthin levels, suggests that the serum level of zeaxanthin may be easily modulated by supplementation and does not necessarily depend on the basal level. However, the level of macular zeaxanthin, but not lutein, of the nonresponding monkey, was high after supplementation. Therefore, the uptake of zeaxanthin into the retina may be highly specific.
Landrum et al.10 and Bone et al.35 reported a gradual increase in macular pigment (MP) with a noninvasive psychophysical method after dietary supplementation of zeaxanthin or lutein in human subjects. It was assumed that the increase in MP corresponded to the increase in serum zeaxanthin or lutein. Our HPLC measurement showed that zeaxanthin levels in the maculae were elevated by feeding a dietary supplement rich in zeaxanthin. This observation supports the conclusion of Bone et al. The average zeaxanthin content in the maculae of the P1-treated group is two times higher than those of the normal and the vehicle-treated groups. Therefore, the uptake of zeaxanthin from serum into the macula was highly effective.
The location of zeaxanthin and lutein in the retina is very unique. In humans, zeaxanthin is highest in the center of the fovea, whereas lutein is relatively abundant in the perifoveal region. Although the level of lutein is higher than zeaxanthin in the central maculae in our rhesus monkeys, the elevated level of zeaxanthin after P1 supplementation showed that the preferential absorption of zeaxanthin also occurs in the central macula, independent of the relative distribution of zeaxanthin and lutein. The absence of any carotenoids in peripheral or equatorial regions in our study further suggests specific uptake mechanisms at the center of the retina.
F. lycii, the red berry of L. barbarum is an important ingredient in Chinese herbal medicine for cataract, glaucoma, and retinitis pigmentosa.13 Whether F. lycii is beneficial in the treatment of these ocular diseases remains to be studied. However, the abundant zeaxanthin in this berry and the ready absorption of its zeaxanthin into serum and the macula of primates may be beneficial in protecting the retina against free radicals and blue light damages.
In summary, we noted significant levels of zeaxanthin and lutein in the maculae of rhesus monkeys with a 1:2 ratio (zeaxanthin to lutein). We also recorded elevated levels of zeaxanthin and lutein in the sera and the maculae of rhesus monkeys after feeding an extract of F. lycii. Therefore, F. lycii is a good source of zeaxanthin to increase circulating and macular zeaxanthin.
| Acknowledgements |
|---|
| Footnotes |
|---|
Commercial relationships policy: N.
Corresponding author: Ivan Y. F. Leung, The Schepens Eye Research Institute, 20 Staniford Street, Boston, MA 02114. ileung{at}vision.eri.harvard.edu
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
F. Khachik, E. London, F. F. de Moura, M. Johnson, S. Steidl, L. DeTolla, S. Shipley, R. Sanchez, X.-Q. Chen, J. Flaws, et al. Chronic Ingestion of (3R,3'R,6'R)-Lutein and (3R,3'R)-Zeaxanthin in the Female Rhesus Macaque Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5476 - 5486. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Johnson, M. Neuringer, R. M. Russell, W. Schalch, and D. M. Snodderly Nutritional Manipulation of Primate Retinas, III: Effects of Lutein or Zeaxanthin Supplementation on Adipose Tissue and Retina of Xanthophyll-Free Monkeys Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 692 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chitchumroonchokchai, J. A. Bomser, J. E. Glamm, and M. L. Failla Xanthophylls and {alpha}-Tocopherol Decrease UVB-Induced Lipid Peroxidation and Stress Signaling in Human Lens Epithelial Cells J. Nutr., December 1, 2004; 134(12): 3225 - 3232. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Neuringer, M. M. Sandstrom, E. J. Johnson, and D. M. Snodderly Nutritional Manipulation of Primate Retinas, I: Effects of Lutein or Zeaxanthin Supplements on Serum and Macular Pigment in Xanthophyll-Free Rhesus Monkeys Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 3234 - 3243. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Y.-F. Leung, M. M. Sandstrom, C. L. Zucker, M. Neuringer, and D. M. Snodderly Nutritional Manipulation of Primate Retinas, II: Effects of Age, n-3 Fatty Acids, Lutein, and Zeaxanthin on Retinal Pigment Epithelium Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 3244 - 3256. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Thomson, Y. Toyoda, A. Langner, F. C. Delori, K. M. Garnett, N. Craft, C. R. Nichols, K. M. Cheng, and C. K. Dorey Elevated Retinal Zeaxanthin and Prevention of Light-Induced Photoreceptor Cell Death in Quail Invest. Ophthalmol. Vis. Sci., November 1, 2002; 43(11): 3538 - 3549. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Toyoda, L. R. Thomson, A. Langner, N. E. Craft, K. M. Garnett, C. R. Nichols, K. M. Cheng, and C. K. Dorey Effect of Dietary Zeaxanthin on Tissue Distribution of Zeaxanthin and Lutein in Quail Invest. Ophthalmol. Vis. Sci., April 1, 2002; 43(4): 1210 - 1221. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |